OWL-LABS
26.1.2021 09:02:03 CET | Business Wire | Press release
Owl Labs , the award-winning leader in immersive and collaborative video conferencing technology and services, today announced an alliance with Ingram Micro, the world’s largest distributor and provider of technology services and solutions. The new distribution agreement expands Owl Labs’ reach across Europe and strengthens Owl Labs’ presence within key European markets.
Through Owl Labs working relationship with Ingram Micro, Owl Labs will now be able to expand the reach and accessibility of its award-winning flagship product, the Meeting Owl Pro, to one centralised distribution warehouse in Straubing, Germany, and from that single point will support its supply chain into 17 distribution centers across Europe, trading across all 28 countries. Ingram Micro serves a diverse base of resellers and 2,000+ of the world’s most recognized IT and mobility technology brands.
With the rapid adoption of hybrid work and remote teams, maintaining effective communication and collaboration regardless of location is more crucial than ever. As more diverse and flexible working patterns continue to become increasingly popular, companies will need to find a better way to connect employees, whether they are in-office or at home. Companies can achieve a seamless collaborative team experience no matter where employees are located with the Meeting Owl Pro. Powered by Owl Labs’ proprietary intelligence technology, the Meeting Owl Pro automatically focuses on who is speaking in a room using audio and visual cues from its high-definition 360° camera, as well as eight microphones and tri-speakers, that have a pickup range of five meters. Through this technology the smart device is able to create a fully immersive, near face-to-face experience for all participants involved, and is also compatible with all popular video conferencing platforms.
“We are thrilled to team up with Ingram Micro, increasing our reach and presence across Europe to expand and strengthen our business. This alliance will make it easier for businesses and educational institutions based in Europe to use Owl Labs’ collaboration technology to help maintain and facilitate clear and effective communication with employees or students, no matter their location.” states Frank Weishaupt, CEO of Owl Labs. “As hybrid and flexible working rises in popularity, there is an increased demand in products and services that help productivity and allow hybrid teams to communicate effectively. We look forward to meeting this demand through our partnership with Ingram Micro.”
Owl Labs' products are used by 50,000+ companies in 156 countries across a wide array of categories, including the likes of the Ogilvy, ClearScore, Bern University of Applied Science, and Prague College. Owl Labs has been recently named AV Technology Awards Communication Technology of the Year, as well as German Design Award Winners and Red Dot Award Recipient. The Owl Labs' Meeting Owl Pro is also named in TIME's List Of The 100 Best Inventions Of 2020.
“ Having the ability to work from anywhere and communicate clearly and securely from everywhere is critical to the future of work,” states Joost Boon, director, Advanced Solutions, UCC Supply Chain and Business Operations, Pan Europe GmbH, Ingram Micro. “We are pleased to welcome Owl Labs to the Ingram Micro Pan Europe portfolio, and look forward to working together with our channel partners to generate greater awareness and demand for Owl Lab’s innovative and immersive video conferencing technology solutions.”
About Owl Labs
Owl Labs is a collaborative technology company revolutionizing the way we connect. Owl Labs creates deeply immersive and inclusive meeting experiences for today’s hybrid workforce and virtual classroom. The company’s flagship product, the award-winning Meeting Owl, features a wifi-enabled, 360-degree camera, mic, and speaker powered by proprietary technology with an automatic zoom that responds to who’s speaking. In 2020, the Meeting Owl Pro was named in TIME’s 100 Best Innovations
.
Owl Labs continues to champion the hybrid work movement with its annual State of Remote Work Report . To learn more about Owl Labs and the full product suite and to join the Work From Anywhere Movement, please visit www.owllabs.com .
About Ingram Micro
Ingram Micro helps businesses realize the promise of technology. It delivers a full spectrum of global technology and supply chain services to businesses around the world. Deep expertise in technology solutions, mobility, cloud, and supply chain solutions enables its business partners to operate efficiently and successfully in the markets they serve. Unrivaled agility, deep market insights and the trust and dependability that come from decades of proven relationships, set Ingram Micro apart and ahead. Discover how Ingram Micro can help you realize the promise of technology. More at www.ingrammicro.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210126005061/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom